A recent study has concluded that a vast majority of Alzheimer’s disease cases can be traced back to one specific gene variant, highlighting the capacity of genetics to influence this debilitating condition. Published on January 16, 2026, this research underscores the significance of the apolipoprotein E (APOE) gene, particularly its alleles in the etiology of Alzheimer’s disease.

Gene Variant Insights

The findings suggest that nearly 90% of Alzheimer’s cases are linked to the common ε3 and the harmful ε4 variants of the APOE gene, while the ε2 allele appears to provide strong protective benefits against developing the disease [1].

Understanding APOE Alleles

The APOE gene is notable for its role in lipid metabolism within the brain and the body. Here are the three main alleles of the APOE gene:

  • ε2: Protective against Alzheimer’s, but rare (0.3-0.6%).
  • ε3: Considered “neutral” and most common.
  • ε4: Increases Alzheimer’s risk, especially in homozygous individuals.

Research Scope

The study involved data from approximately 470,000 participants from major cohorts, including the UK Biobank, FinnGen, the A4 Study, and the Alzheimer’s Disease Genetics Consortium. The outcomes assessed were the clinical diagnoses of Alzheimer’s disease, neuropathological findings, and positivity for amyloid-β on PET scans.

Population Attributable Fractions (PAFs)

Population attributable fractions (PAFs) were calculated to estimate the proportion of Alzheimer’s disease cases that could be directly associated with specific APOE genotypes:

Cohort PAF for Alzheimer’s PAF for All-Cause Dementia
UK Biobank 71.5% 44.4%
FinnGen 92.7% 45.6%
A4 Study 85.4% (Cerebral amyloidosis) N/A

Controversy and Critiques

Despite the strong correlations marked by this study, not all experts agree with the interpretation of the data. Critics argue that the methodologies may reflect an overestimation of the genetic risk linked to Alzheimer’s by treating the ε2 allele as the baseline variant. Anneke Lucassen, a Professor of Genomic Medicine at the University of Oxford, commented on the potential flaws in framing the ε3 and ε4 alleles as 'at risk.'

Furthermore, the multifactorial nature of Alzheimer’s disease cannot be ignored. Dr. Richard Oakley of the Alzheimer’s Society emphasized that genetics is just one part of a larger picture that includes environmental factors and lifestyle choices, which play a crucial role in the onset of Alzheimer’s [3].

A Shift in Medical Paradigms

The selection of a protective variant as the baseline suggests a paradigm shift. This study challenges the conventional view that “normal” genes are merely neutral, instead proposing that each variant has significant ramifications on health outcomes. This aligns with geroscience, which posits that aging itself can be viewed as a pathological process.

As Dr. Williams stated, the application of gene editing techniques to address genetic risk factors is within reach, potentially offering groundbreaking advancements in Alzheimer’s prevention and treatment.

Limitations and Future Directions

While the study presents noteworthy insights, it is essential to acknowledge its limitations, including the rarity of the ε2 homozygote reference group and the concentration of participants predominantly from European ancestry, which may restrict the applicability of the findings across diverse populations.

Conclusion

Understanding the complexities of APOE and its implications on Alzheimer's disease continues to evolve. Future research must aim to broaden the diversity of studied populations and explore genetic interventions while recognizing the importance of lifestyle factors.

Literature Cited

  1. Williams, D. M., Heikkinen, S., Hiltunen, M., FinnGen, Davies, N. M., & Anderson, E. L. (2026). The proportion of Alzheimer’s disease attributable to apolipoprotein E. npj Dementia, 2(1), 1.
  2. Troutwine, B. R., Hamid, L., Lysaker, C. R., Strope, T. A., & Wilkins, H. M. (2022). Apolipoprotein E and Alzheimer’s disease. Acta Pharmaceutica Sinica B, 12(2), 496-510.
  3. Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., … & Mukadam, N. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 404(10452), 572-628.

About the Author

Arkadi Mazin is a seasoned journalist with interests in science, policy, and philosophy. With a background in economics and international relations, he advocates for prioritizing life extension and its associated benefits for society.

© 2026 Lifespan Research Institute – ALL RIGHTS RESERVED